You are here

  • Home
  • Archive
  • Volume 29, Issue 5
  • A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen

Article Text

Article menu
Download PDFPDF
Original Article
A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen
  1. Brooke A Schlappe1,
  2. Qin C Zhou2,
  3. Roisin O'Cearbhaill3,
  4. Alexia Iasonos2,
  5. Robert A Soslow4,
  6. Nadeem R Abu-Rustum1 and
  7. Jennifer J Mueller1
  1. 1 Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
  2. 2 Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
  3. 3 Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
  4. 4 Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
  1. Correspondence to Dr Jennifer J Mueller, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA; muellerj{at}mskcc.org

Abstract

Objective We described progression-free survival and overall survival in patients with primary mucinous ovarian cancer receiving adjuvant gynecologic versus gastrointestinal chemotherapy regimens.

Methods We identified all primary mucinous ovarian cancer patients receiving adjuvant gynecologic or gastrointestinal chemotherapy regimens at a single institution from 1994 to 2016. Gynecologic pathologists using strict pathologic/clinical criteria determined diagnosis. Adjuvant therapy was coded as gynecologic or gastrointestinal based on standard agents and schedules. Clinical/pathologic/treatment characteristics were recorded. Wilcoxon rank-sum test was used for continuous variables, and Fisher’s exact test for categorical variables. Progression-free and overall survival were calculated using the Kaplan-Meier method, applying landmark analysis.

Results Of 62 patients identified, 21 received adjuvant chemotherapy: 12 gynecologic, 9 gastrointestinal. Median age (in years) at diagnosis: 58 (range 25–68) gynecologic cohort, 38 (range 32–68) gastrointestinal cohort (p=0.13). Median body mass index at first post-operative visit: 25 kg/m2 (range 18–31) gynecologic cohort, 23 kg/m2 (range 18–31) gastrointestinal cohort (p=0.23). History of smoking: 6/12 (50%) gynecologic cohort, 3/9 (33%) gastrointestinal cohort (p=0.66). Stage distribution in gynecologic and gastrointestinal cohorts, respectively: stage I: 9/12 (75%) and 3/9 (33%); stage II: 2/12 (17%) and 1/9 (11%); stage III: 1/12 (8%) and 5/9 (56%) (p=0.06). Grade distribution in gynecologic and gastrointestinal cohorts, respectively: grade 1: 8/12 (67%) and 1/9 (13%); grade 2/3: 4/12 (33%) and 7/9 (88%) (p=0.03). Three-year progression-free survival: 90.9% (95% CI 50.8% to 98.7 %) gynecologic, 53.3% (95% CI 17.7% to 79.6%) gastrointestinal. Three-year overall survival: 90.9% (95% CI 50.8% to 98.7%) gynecologic, 76.2% (95% CI 33.2% to 93.5%) gastrointestinal.

Conclusion Ongoing international collaborative research may further define associations between chemotherapy regimens and survival.

  • mucinous ovarian cancer
  • chemotherapy
  • gastrointestinal
  • oncologic outcomes

https://doi.org/10.1136/ijgc-2018-000150

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors All the authors have reviewed the manuscript, and approved it for publication. Each of the authors has contributed substantially to this study and takes responsibility for its contents. Conception and design: BAS, JJM, Data analysis and interpretation: BAS, QCZ, REO, AI, RAS, NRA, JJM. Manuscript writing: BAS, AI. Revising manuscript critically: BAS, QCZ, REO, RAS, NRA, JJM. Final approval of manuscript: all authors.

    • Funding This study was funded in part through the NIH/NCI Support Grant P30 CA008748. Dr. Abu-Rustum reports grants from Stryker/Novadaq, grants from Olympus, and grants from GRAIL, outside the submitted work. Dr. O’Cearbhaill reports personal fees from Clovis and personal fees from Tesaro, outside the submitted work.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement All data relevant to the study are included in the article or uploaded as supplementary information.